Description:
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib
that can be given to patients with low or intermediate-1 risk MDS. The safety of this drug
will also be studied, and whether it can help to control the disease.
Title
- Brief Title: Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Official Title: Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Clinical Trial IDs
- ORG STUDY ID:
2013-0012
- SECONDARY ID:
NCI-2013-02204
- NCT ID:
NCT01895842
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Ruxolitinib | Jakafi, INCB018424, INC424 | Ruxolitinib |
Purpose
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib
that can be given to patients with low or intermediate-1 risk MDS. The safety of this drug
will also be studied, and whether it can help to control the disease.
Detailed Description
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to a study
group based on when you join this study. Up to 4 groups of 3-6 participants will be enrolled
in Part 1 of the study, and up to 7 participants will be enrolled in Part 2.
If you are enrolled in Part 1, the dose of ruxolitinib you receive will depend on when you
joined this study. The first group of participants will receive the lowest dose of
ruxolitinib. The second group of participants will receive the lowest dose of ruxolitinib for
1 cycle and if no intolerable side effects are seen, the dose will increase to the next
higher dose for Cycles 2 and beyond. The third group of participants will receive the higher
dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the
dose will be increased for Cycles 2 and beyond. The fourth group of participants will take
the higher dose taken by the third group for 1 cycle and if no intolerable side effects are
seen, the dose will increase to the next higher dose for Cycles 2 and beyond.
If you are enrolled in Part 2, you will receive ruxolitinib at the highest dose that was
tolerated in Part 1.
Study Drug Administration:
Each cycle is 28 days.
You will take ruxolitinib by mouth 2 times a day (about 12 hours apart), with or without
food.
Study Visits:
One (1) time a week during Cycles 1 and 2 and then on Day 1 of Cycles 3 and beyond, blood
(about 2-3 teaspoons) will be drawn for routine tests. On Day 28 of each cycle and Day 1 of
Cycles 3 and beyond, this blood may also be used for cytogenetic testing if your doctor
thinks it is needed.
On Day 28 of Cycles 1 and 2 and then every 3 cycles, you will have a bone marrow aspiration
to check the status of the disease and for cytogenetic testing, if your doctor thinks it is
needed.
On Day 28 of Cycle 1 and Day 1 of Cycles 3 and beyond, you will have a physical exam.
If the doctor thinks it is needed, urine will be collected on Day 1 of each cycle for routine
tests.
Length of Dosing:
You may continue taking the study drug for up to 2 years. You will no longer be able to take
the study drug if the disease gets worse, if intolerable side effects occur, or if you are
unable to follow study directions.
Your participation on the study will be over after the end-of-dosing visit.
End-of-Dosing Visit:
After you are finished taking the study drug:
- You will have a physical exam.
- You will have a bone marrow aspiration to check the status of the disease.
- Blood (about 2-3 teaspoons) will be drawn for routine tests. This blood may also be used
for cytogenetic testing if your doctor thinks it is needed.
Follow-up Visit:
About 30 days after the End-of-Dosing visit, a member of the study team will contact you by
phone. You will be asked how you are feeling and about any side effects you may be
experiencing. This phone call should take 10-15 minutes.
This is an investigational study. Ruxolitinib is FDA approved and commercially available for
the treatment of myelofibrosis. Its use in this study is investigational. The study doctor
can explain how ruxolitinib is designed to work.
Up to 31 participants will be enrolled in this study. All will take part at MD Anderson.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Ruxolitinib | Experimental | Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.
If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1. | |
Eligibility Criteria
Inclusion Criteria:
1. Patients with previously treated low or intermediate-1 risk MDS by the IPSS
classification (this is defined in table 1)
2. Patients must have one of the following: elevated b2-microglobulin levels (defined as
2 times compared to normal), carry a JAK2 mutation, or presence of phosphorylated p65
NF-kB component in at least 5% of bone marrow cells.
3. Signed informed consent indicating that patients are aware of the investigational
nature of this study in keeping with the policies of UTMDACC.
4. Age >/= 18 years old
5. Prior therapy with growth factor support, lenalidomide, 5-azacytidine, decitabine or
other investigational agents are allowed. A four week wash out period will be required
before receiving study medication.
6. Patients must have the following non-hematologic values Aspartate aminotransferase
(AST/SGOT) and alanine aminotransferase (ALT/SGPT) </= 2.5 x Upper Limit of Normal
(ULN) or </= 5.0 x ULN if hepatic involvement is present; Serum bilirubin </= 2 x ULN;
Serum creatinine </= 2 x ULN or 24-hour creatinine clearance >/= 60 ml/min
7. Patients with Childbearing potential must agree to use appropriate forms of birth
control
Exclusion Criteria:
1. Previously untreated low or intermediate-1 risk MDS patients because there are
approved therapies for these patients.
2. Uncontrolled undercurrent illness that in the opinion of the treating physician would
contraindicate the use of the drug.
3. Patients with active infections including uncontrolled HIV infection, active hepatitis
B, C, or any other symptomatic systemic infection requiring active therapy will be
excluded from study
4. Patients receiving potent CYP3A4 (such as but not limited to boceprevir,
clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole,
lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir,
saquinavir, telaprevir, telithromycin, voriconazole) inhibitors will be excluded from
the study.
5. Women who are pregnant or lactating.
6. Patients with a white blood cell count of more than 30x10^3 K/uL will not be eligible
for this study.
7. Patients that have received prior allogeneic stem cell transplantation are excluded
from this study.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Maximum Tolerated Dose (MTD) of Ruxolitinib |
| Time Frame: | 28 days |
| Safety Issue: | |
| Description: | Maximum tolerated dose (MTD) is the maximum dose at which <33% of patients experience a dose limiting toxicity (DLT). Dose limiting toxicity defined as any grade 3 or higher non-hematologic toxicity. |
Secondary Outcome Measures
| Measure: | Number of Participants with Response of Ruxolitinib |
| Time Frame: | 8 weeks |
| Safety Issue: | |
| Description: | Criteria for response follows the modified International Working Group (IWG) response criteria for altering natural history of MDS defined as: Complete Remission, Partial Remission, Stable Disease, Cytogenetic Response, Disease Progression. |
Details
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | M.D. Anderson Cancer Center |
Trial Keywords
- Leukemia
- Myelodysplastic syndrome
- MDS
- Low or intermediate-1 risk
- Maximum tolerated dose
- MTD
- Ruxolitinib
- Jakafi
- INCB018424
- INC424
Last Updated
April 16, 2019
